CAMBRIDGE, Mass., Dec. 05, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases, today announced the election of biopharmaceutical veteran Michael W. Bonney to its board of directors.
From 2003 through its acquisition by Merck in 2014, Mr. Bonney was the chief executive officer of Cubist Pharmaceuticals. Mr. Bonney is currently the chief executive officer and chair of Kaleido Biosciences, a biotechnology company focused on the development of novel chemistries to unlock the power of the human microbiome. He also serves as chair of the boards of Alnylam Pharmaceuticals, Inc. and Magenta Therapeutics, is a member of the board for Celgene Corporation and a former partner at Third Rock Ventures. Additionally, Mr. Bonney is a trustee of the four healthcare dedicated closed end mutual funds managed by Tekla Capital Management.
“Sarepta and its board of directors are greatly enhanced with the appointment to our board of Mike Bonney, one of the most respected biopharmaceutical leaders,” said M. Kathleen Behrens, Ph.D., chair of Sarepta’s board of directors. “Mike’s list of accomplishments is long and his impact on this industry has been profound. We will leverage Mike’s experience as we execute our mission to improve the lives of those suffering from rare diseases.”
“Sarepta stands at a moment of great inflection as we continue the successful launch of our first therapy for the treatment of Duchenne muscular dystrophy while accelerating with a sense of urgency our rich precision genetic medicine pipeline,” said Douglas Ingram, Sarepta’s president and chief executive officer. “I am fortunate to have access to the insight and guidance of someone of Mike’s impeccable credentials and nearly unique experience across all aspects of the biopharmaceutical ecosystem as we execute our ambitious plan and fulfil our important commitments to our patients.”
“Sarepta’s mission and technology are critically important for children with DMD, their families and potentially a range of patients living with other diseases,” said Mr. Bonney. “I am delighted to apply my experience to help the company realize its goal to make an important impact for these underserved patient populations.”
About Sarepta Therapeutics
Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates. For more information, please visit www.sarepta.com.
Forward-Looking Statements
This press release contains forward-looking statements. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements regarding Sarepta’s plan to leverage Mr. Bonney’s experience as it executes its mission to improve the lives of those suffering from rare disease; Sarepta’s plan to continue the successful launch of its first therapy for the treatment of DMD while accelerating with a sense of urgency Sarepta’s rich precision genetic medicine pipeline; Mr. Bonney’s credential and experience being invaluable to Sarepta as it executes its ambitious plan and fulfils its important commitment to its patients; Sarepta’s mission and technology being critically important for children with DMD, their families and potentially a range of patients living with other diseases; and Mr. Bonney’s intent to apply his experience to help Sarepta realize its goal to make an important impact for these underserved patient population.
These forward-looking statements involve risks and uncertainties, many of which are beyond Sarepta’s control. Known risk factors include, among others: Sarepta may not be able to meet expectations with respect to the sales of its first therapy for the treatment of DMD; Sarepta may not be able to complete clinical trials required by the FDA or other regulatory authorities for approval of any of its product candidates; the results of Sarepta’s ongoing research and development efforts and clinical trials for its product candidates may not be positive or consistent with prior results or demonstrate a safe treatment benefit; Sarepta may not be able to execute on its business plans, including meeting its expected or planned regulatory milestones and timelines, clinical development plans, and bringing its products to U.S. and ex-U.S. markets for various reasons including possible limitations of company financial and other resources, manufacturing limitations that may not be anticipated or resolved for in a timely manner, and regulatory, court or agency decisions, such as decisions by the United States Patent and Trademark Office with respect to patents that cover Sarepta’s product candidates; and those risks identified under the heading “Risk Factors” in Sarepta’s most recent Annual Report on Form 10-K for the year ended December 31, 2016 and most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company which you are encouraged to review.
Any of the foregoing risks could materially and adversely affect the Company’s business, results of operations and the trading price of Sarepta’s common stock. For a detailed description of risks and uncertainties Sarepta faces, you are encouraged to review Sarepta's 2016 Annual Report on Form 10-K and most recent Quarterly Report on Form 10-Q for the quarter ended September 30, 2017 filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by Sarepta. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
Source: Sarepta Therapeutics, Inc.
Media and Investors:
Sarepta Therapeutics, Inc.
Ian Estepan, 617-274-4052
iestepan@sarepta.com
or
W2O Group
Brian Reid, 212-257-6725
breid@w2ogroup.com